{"gene":"USP30","run_date":"2026-06-11T09:02:06","timeline":{"discoveries":[{"year":2008,"finding":"USP30 is a deubiquitinating enzyme embedded in the mitochondrial outer membrane; depletion by RNAi induces elongated, interconnected mitochondria dependent on mitofusin activity, and this phenotype is rescued by enzymatically active USP30 but not catalytic mutants, establishing USP30 as a regulator of mitochondrial morphology through its DUB activity.","method":"RNAi knockdown, ectopic expression of wild-type vs. catalytic-dead USP30, fluorescence microscopy of mitochondrial morphology, subcellular fractionation","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal loss-of-function and rescue with catalytic mutant, single lab, two orthogonal methods (RNAi + overexpression with mutagenesis)","pmids":["18287522"],"is_preprint":false},{"year":2014,"finding":"USP30 localizes to mitochondria and opposes Parkin-mediated mitophagy: overexpression of USP30 removes ubiquitin from Parkin substrates on damaged mitochondria and blocks mitophagy, while USP30 knockdown enhances mitochondrial degradation. Global ubiquitination site profiling identified multiple mitochondrial substrates oppositely regulated by Parkin and USP30. In Drosophila, USP30 knockdown rescues defective mitophagy caused by pathogenic Parkin mutations and protects dopaminergic neurons against paraquat toxicity.","method":"Overexpression/knockdown, global ubiquitination site profiling (mass spectrometry), mitophagy assays, Drosophila genetic rescue experiments","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (proteomics, cell biology, in vivo genetics), replicated across cell and animal models","pmids":["24896179"],"is_preprint":false},{"year":2014,"finding":"The diterpenoid derivative 15-oxospiramilactone (S3) inhibits USP30, leading to non-degradative ubiquitination of Mfn1/2 that enhances mitofusin activity and promotes mitochondrial fusion, uncovering that USP30-dependent deubiquitination of mitofusins suppresses their fusion activity.","method":"Chemical inhibition with S3, mitochondrial fusion assays, ubiquitination assays for Mfn1/2, cell lines deficient in Mfn1 or Mfn2","journal":"Cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional rescue with inhibitor and genetic target identification, single lab, two orthogonal methods","pmids":["24513856"],"is_preprint":false},{"year":2015,"finding":"USP30 deubiquitylates TOM20 opposing Parkin-dependent ubiquitylation; USP30 depletion enhances depolarization-induced cell death in Parkin-overexpressing cells and sensitizes cancer cells to BH3-mimetics by regulating BAX/BAK-dependent apoptosis, establishing a role for USP30 in controlling the mitochondrial apoptotic threshold.","method":"USP30 depletion (siRNA/shRNA), cell death assays, ubiquitylation assays for TOM20, BH3-mimetic sensitivity assays","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined apoptotic phenotype and substrate identification, single lab, two orthogonal methods","pmids":["25739811"],"is_preprint":false},{"year":2017,"finding":"Crystal structures of human USP30 bound to monoubiquitin and Lys6-linked diubiquitin reveal unique ubiquitin-binding interfaces that confer Lys6-linkage preference for cleavage. Distally phosphorylated (pSer65) ubiquitin chains impair USP30 activity. Lys6-linkage-specific affimers identified TOM20 as a mitochondrial substrate for Lys6-polyubiquitination regulated by USP30.","method":"X-ray crystallography, in vitro DUB activity assays, phospho-ubiquitin chain inhibition assays, Lys6-specific affimer pulldowns, quantitative proteomics","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures with functional validation (activity assays, mutagenesis-informed substrate identification, multiple orthogonal methods)","pmids":["28945249"],"is_preprint":false},{"year":2018,"finding":"USP30 regulates basal pexophagy independently of PINK1 and Parkin: a fraction of endogenous USP30 localizes to peroxisomes where it suppresses basal pexophagy. Additionally, USP30 acts upstream of PINK1 in basal mitophagy by modulating PINK1-substrate availability, establishing dual organelle roles.","method":"Mitophagy reporter systems, immunofluorescence/fractionation to show peroxisomal localization, genetic KO/knockdown of USP30, PINK1 pathway analysis","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent mitophagy reporter systems, localization experiments, genetic perturbations, replicated with two distinct assays","pmids":["29895712"],"is_preprint":false},{"year":2018,"finding":"GNPAT recruits USP30, which deubiquitylates and stabilizes DRP1, thereby promoting mitochondrial fission and hepatocarcinogenesis; USP30 interaction with DRP1 was established by Co-IP.","method":"Co-immunoprecipitation, ubiquitination assays, DRP1 protein stability assays, loss-of-function experiments in HCC cells","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP and ubiquitination assay, single lab, two orthogonal methods identifying substrate","pmids":["30143522"],"is_preprint":false},{"year":2019,"finding":"USP30 localizes to peroxisomes and prevents pexophagy by counteracting the peroxisomal E3 ubiquitin ligase PEX2; USP30 overexpression blocks amino-acid-starvation-induced pexophagy, and its depletion triggers basal pexophagy, establishing a PEX2–USP30 ubiquitin axis controlling peroxisome abundance.","method":"USP30 overexpression/depletion, pexophagy assays, peroxisomal localization by microscopy, genetic epistasis with PEX2","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (PEX2/USP30), direct localization, functional pexophagy assays, replicates prior localization finding from different lab","pmids":["30700497"],"is_preprint":false},{"year":2020,"finding":"In induced neurons (iNeurons), USP30 knockout reveals that elevated ubiquitylation targets concentrate on mitochondrial translocon (TOM complex) components; USP30 loss accelerates pS65-Ub accumulation and mitophagic flux modestly without altering ubiquitylation kinetics of the vast majority of Parkin targets. Basally, ubiquitylated translocon import substrates accumulate in USP30-/- iNeurons, indicating a quality control function for USP30 at the TOM complex.","method":"Quantitative ubiquitylomics/proteomics in USP30-/- iNeurons, CRISPR KO, mitophagy flux assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — quantitative proteomics with genetic KO in physiologically relevant neuronal model, multiple orthogonal methods, independent of prior studies","pmids":["32142685"],"is_preprint":false},{"year":2020,"finding":"USP30 sets a trigger threshold for PINK1-Parkin amplification of mitochondrial ubiquitylation: TOM20 ubiquitylation is a robust biomarker for USP30 loss/inhibition, and USP30 deubiquitylation of TOM complex components dampens the local ubiquitin signal at the site of PINK1 accumulation following depolarization, slowing Parkin-dependent amplification.","method":"Selective USP30 inhibitor (FT3967385), proteomics in SH-SY5Y cells, comparison of genetic KO vs chemical inhibition, pS65-Ub kinetics, mitophagy assays","journal":"Life science alliance","confidence":"High","confidence_rationale":"Tier 2 / Strong — chemical inhibitor vs. genetic KO comparison with quantitative proteomics, defines mechanistic model with multiple orthogonal readouts","pmids":["32636217"],"is_preprint":false},{"year":2020,"finding":"Tryptophan residue W475 near the USP30 active site contributes to diubiquitin linkage selectivity; replacement with noncanonical Trp analogues modulates activity and K6-specificity, with 3-benzothienyl-l-alanine inducing unique K6-specificity.","method":"Genetic code expansion/noncanonical amino acid incorporation, in vitro DUB activity assays with diubiquitin substrates, X-ray crystallography of PylRS-ncAA complexes","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro mutagenesis with noncanonical residues and structural data, single lab, novel mechanistic insight into active site","pmids":["32484330"],"is_preprint":false},{"year":2021,"finding":"USP30 deubiquitylates NLRP3, activating the NLRP3 inflammasome; this interaction was verified by Co-IP and ubiquitination assays, and USP30 knockdown or inhibition reduces NLRP3 inflammasome activity in skin fibroblasts.","method":"Co-immunoprecipitation, ubiquitination assays, shRNA knockdown, USP30 inhibitor MF-094, NLRP3 inflammasome activity readouts","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP plus ubiquitination assay, single lab, two orthogonal methods identifying novel substrate","pmids":["34883112"],"is_preprint":false},{"year":2022,"finding":"A peptide (Q14) derived from the transmembrane domain of USP30 inhibits USP30 via an autoinhibitory allosteric mechanism; binding sites between Q14 and USP30 were identified by fluorescence polarization and microscale thermophoresis, proposing that the TM domain can allosterically regulate USP30 catalytic activity.","method":"Fluorescence polarization, microscale thermophoresis, peptide binding studies, mitophagy assays, LC3-interaction via LIR motif characterization","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — binding assays with functional readout, single lab, two orthogonal binding methods but allosteric mechanism inferred rather than directly structurally proven","pmids":["34989313"],"is_preprint":false},{"year":2022,"finding":"A benzosulfonamide inhibitor (USP30inh) binds to the cleft between the USP30 thumb and palm subdomains, preventing ubiquitin C-terminus guidance to the active site; hydrogen-deuterium exchange MS and computational docking reveal compound-induced structural rearrangements at this cleft rather than direct active-site occlusion.","method":"Activity-based protein profiling MS (selectivity against 49 DUBs), enzyme kinetics, hydrogen-deuterium exchange MS, computational docking","journal":"Molecular & cellular proteomics","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple structural/biochemical methods (HDX-MS, kinetics, ABPP) in single rigorous study defining inhibitor binding mode","pmids":["37385347"],"is_preprint":false},{"year":2023,"finding":"USP30 interacts with and deubiquitylates Snail via K48-linked polyubiquitin chains, stabilizing Snail protein and promoting EMT in breast cancer cells; verified by Co-IP and ubiquitination assays.","method":"Co-immunoprecipitation, ubiquitination assays, knockdown/overexpression, proliferation/invasion assays","journal":"Cancer gene therapy","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP and ubiquitination assay, single lab, two orthogonal methods identifying novel non-mitochondrial substrate","pmids":["38146008"],"is_preprint":false},{"year":2024,"finding":"CDK5 phosphorylates USP30 at serine 216 to stabilize USP30 protein; CDK5-USP30 signaling suppresses mitophagy and activates MAVS-mediated inflammation in MPTP/MPP+-induced Parkinson's disease models.","method":"Phosphorylation site identification (Ser216), CDK5 inhibition experiments, USP30 protein stability assays, MAVS pathway analysis, mitophagy assays in BV2 cells and in vivo MPTP mouse model","journal":"Ecotoxicology and environmental safety","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — phosphorylation site mapped and functional consequence shown, single lab, in vitro and in vivo evidence","pmids":["38772138"],"is_preprint":false},{"year":2024,"finding":"NPRC recruits USP30 to deubiquitinate C/EBPβ at K149 (K48-linked polyubiquitination), stabilizing C/EBPβ and driving lipid metabolism reprogramming in MAFLD; the DNA-binding domain of C/EBPβ interacts with USP30, and the ANPR region of NPRC binds USP30.","method":"Proteomics, ubiquitination analysis, Co-immunoprecipitation, domain mapping experiments","journal":"Metabolism: clinical and experimental","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP and ubiquitination site mapping, single lab, two orthogonal methods identifying novel substrate and regulatory complex","pmids":["39433172"],"is_preprint":false},{"year":2024,"finding":"HMGA2 stabilizes S100A6 by recruiting USP30, inhibiting S100A6 ubiquitination/degradation; demonstrated by Co-IP and mass spectrometry in ovarian cancer cells.","method":"Co-immunoprecipitation, mass spectrometry, ubiquitination assays, rescue experiments","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP/MS study, single lab, novel substrate claim with limited mechanistic follow-up","pmids":["39694080"],"is_preprint":false},{"year":2024,"finding":"USP30 binds to and deubiquitylates FTO, protecting it from proteasomal degradation; USP30 senses serine/glycine levels to regulate FTO stability, which in turn demethylates PHGDH/PSAT1 mRNAs promoting serine biosynthesis in colorectal cancer.","method":"Co-immunoprecipitation, ubiquitination assays, proteomic/metabolomic analyses, m6A demethylation assays","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP and ubiquitination assays identifying novel substrate and metabolite-sensing function, single lab, multiple orthogonal metabolic readouts","pmids":["41652187"],"is_preprint":false},{"year":2024,"finding":"USP30 deubiquitylates TOMM40, reducing its ubiquitination and stabilizing it; USP30 knockdown reduces TOMM40 protein levels and suppresses breast cancer cell proliferation and angiogenesis, establishing TOMM40 as a USP30 substrate in cancer.","method":"Co-immunoprecipitation, ubiquitination assays, knockdown experiments, cell proliferation/angiogenesis assays","journal":"Journal of biochemical and molecular toxicology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP and ubiquitination assay, single lab, two orthogonal methods","pmids":["40227042"],"is_preprint":false},{"year":2025,"finding":"Crystal structure of human USP30 in complex with a specific inhibitor (enabled by chimeric protein engineering) reveals that the inhibitor occupies a cryptic pocket induced by a compound-driven conformation of the USP30 switching loop; the Leu73 ubiquitin-binding site constitutes a common ligandability hotspot for USP deubiquitinases.","method":"X-ray crystallography of chimeric USP30–inhibitor complex, chimeric protein engineering strategy, structure-activity relationship analysis","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with compound-induced conformational analysis, peer-reviewed, mechanistically validates cryptic pocket and identifies specific inhibitor binding residues","pmids":["40325251"],"is_preprint":false},{"year":2025,"finding":"A cyanopyrrolidine-containing covalent inhibitor (USP30-I-1) binds tightly near the catalytic cysteine (Cys77) of USP30 in a pocket along the thumb and palm domains, preventing ubiquitin substrate binding; HDX-MS reveals structural rearrangements that differ slightly from the benzosulfonamide binding mode, providing molecular basis for differential selectivity.","method":"Enzyme kinetics, hydrogen-deuterium exchange MS, activity-based protein profiling, selectivity profiling against DUB panel","journal":"Journal of proteome research","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple structural/biochemical methods (HDX-MS, kinetics, ABPP) in single study with rigorous selectivity profiling","pmids":["39804742"],"is_preprint":false},{"year":2025,"finding":"USP30 deubiquitylates and stabilizes HK1 and HK2 by preferentially removing atypical ubiquitin chains; Lys144 of HK2 is the critical regulatory site, and USP30-mediated deubiquitination enhances HK2 stability, mitochondrial localization, VDAC1 binding, and hexokinase activity to promote glycolysis and tumor progression.","method":"Co-immunoprecipitation, quantitative proteomics and ubiquitinomics, site-directed mutagenesis (K144R), HK2 activity assays, mitochondrial fractionation","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution approach with mutagenesis at defined substrate lysine, quantitative ubiquitinomics, in vitro enzyme activity, multiple orthogonal methods in single study","pmids":["41688443"],"is_preprint":false},{"year":2025,"finding":"USP30 depletion destabilizes methionine adenosyltransferase 2A (MAT2A) through a deubiquitination-dependent mechanism, lowering SAM levels, reducing global DNA methylation, and upregulating miR-30a-5p to suppress MDM2 and NFAT5, thereby maintaining endothelial cell barrier function via a mitophagy-independent pathway.","method":"EC-specific USP30 knockout mice, LPS/ischemia-reperfusion lung injury models, ubiquitination assays for MAT2A, SAM level measurement, DNA methylation assays, miRNA expression","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic model plus multiple orthogonal biochemical readouts, single lab, novel mitophagy-independent substrate/pathway","pmids":["41104980"],"is_preprint":false},{"year":2025,"finding":"USP30 loss or pharmacological inhibition improves mitochondrial morphology, increases membrane potential and ATP levels with decreased oxygen consumption (suggesting more efficient mitochondrial network), and these morphological changes are independent of PINK1 or Parkin.","method":"CRISPR/Cas9 KO, CRISPRi knockdown, pharmacological inhibition, mitophagy reporters, electrophysiology, mitochondrial membrane potential and ATP assays in cell lines and iPSC-derived neurons","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic and pharmacological approaches with functional readouts, preprint, PINK1/Parkin independence established by epistasis","pmids":[],"is_preprint":true},{"year":2024,"finding":"Proximity-labelling ubiquitomics (APEX2 + K-ε-GG enrichment) identifies TOMM20, FKBP8, and LETM1 as USP30-proximal substrates; LETM1 is deubiquitinated in a USP30-dependent manner as a previously undescribed candidate substrate.","method":"APEX2 proximity labelling, ubiquitin remnant (K-ε-GG) enrichment, quantitative mass spectrometry, USP30 inhibition","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab preprint, proximity labelling identifies candidate substrates but direct deubiquitination of LETM1 not yet fully validated by orthogonal methods","pmids":[],"is_preprint":true}],"current_model":"USP30 is a mitochondrial outer membrane-anchored deubiquitinase (also present on peroxisomes) that preferentially cleaves Lys6-linked polyubiquitin chains—a selectivity explained by its crystal structure—and opposes PINK1/Parkin-driven mitophagy by removing ubiquitin from substrates including TOM20, TOM complex components, Mfn1/2, DRP1, and HK1/2; it also regulates pexophagy by counteracting PEX2-dependent ubiquitination, controls the apoptotic threshold via BAX/BAK, and engages additional substrates (Snail, FTO, NLRP3, MAT2A) in non-mitochondrial contexts, with its activity dampened by pSer65-ubiquitin chains generated by PINK1 and positively regulated by CDK5-mediated phosphorylation at Ser216."},"narrative":{"mechanistic_narrative":"USP30 is a mitochondrial outer membrane-anchored deubiquitinase that regulates mitochondrial morphology and quality control by reversing ubiquitin signals on outer-membrane proteins [PMID:18287522, PMID:24896179]. It opposes PINK1/Parkin-driven mitophagy: USP30 removes ubiquitin from Parkin substrates on damaged mitochondria and blocks their degradation, while its loss enhances mitophagic flux and rescues defective mitophagy in Drosophila Parkin mutants [PMID:24896179]. Mechanistically, USP30 deubiquitylates components of the TOM translocon, including TOM20 and TOMM40, thereby dampening the local ubiquitin signal at sites of PINK1 accumulation and setting a trigger threshold for Parkin-dependent amplification [PMID:25739811, PMID:32636217]; in neurons its loss causes ubiquitylated translocon import substrates to accumulate, defining a quality-control function at the TOM complex [PMID:32142685]. Crystal structures of USP30 bound to monoubiquitin and Lys6-linked diubiquitin reveal ubiquitin-binding interfaces that confer Lys6-linkage cleavage preference, and distally pSer65-phosphorylated ubiquitin chains impair USP30 activity [PMID:28945249]. Beyond translocon control, USP30 deubiquitylates and tunes the activity or stability of mitochondrial dynamics factors (Mfn1/2, DRP1), regulates the BAX/BAK-dependent apoptotic threshold, and counteracts the peroxisomal E3 ligase PEX2 to suppress basal pexophagy, giving it a dual organelle role [PMID:24513856, PMID:25739811, PMID:30143522, PMID:30700497]. CDK5 phosphorylates USP30 at Ser216 to stabilize the protein and suppress mitophagy [PMID:38772138]. In non-mitochondrial contexts USP30 stabilizes additional substrates including Snail, FTO, MAT2A, NLRP3 and HK1/2 to influence EMT, serine biosynthesis, methylation, inflammasome activity and glycolysis [PMID:34883112, PMID:38146008, PMID:41652187, PMID:41688443, PMID:41104980]. USP30 is an actively pursued drug target, with multiple inhibitor classes mapped to distinct binding modes near the catalytic and ubiquitin-binding sites [PMID:37385347, PMID:40325251, PMID:39804742].","teleology":[{"year":2008,"claim":"Established that USP30 is an outer-membrane deubiquitinase whose catalytic activity controls mitochondrial morphology, answering what cellular process this DUB governs.","evidence":"RNAi knockdown with wild-type vs catalytic-dead rescue and mitochondrial morphology imaging","pmids":["18287522"],"confidence":"High","gaps":["Substrates mediating the morphology phenotype not identified","Link to mitophagy not yet established"]},{"year":2014,"claim":"Defined USP30 as an antagonist of Parkin-mediated mitophagy and identified mitochondrial substrates oppositely regulated by Parkin, explaining how it counteracts mitochondrial clearance.","evidence":"Overexpression/knockdown, global ubiquitination site proteomics, and Drosophila genetic rescue of pathogenic Parkin mutants","pmids":["24896179"],"confidence":"High","gaps":["Linkage specificity of cleaved chains not yet resolved","Direct vs indirect deubiquitylation of each profiled substrate unclear"]},{"year":2014,"claim":"Showed that USP30 deubiquitylation of mitofusins suppresses their fusion activity, mechanistically connecting USP30 to mitochondrial fusion.","evidence":"Chemical inhibition by 15-oxospiramilactone with Mfn1/2 ubiquitination and fusion assays in Mfn-deficient lines","pmids":["24513856"],"confidence":"Medium","gaps":["Inhibitor selectivity beyond USP30 not fully excluded","Direct enzymatic action on Mfn chains not reconstituted"]},{"year":2015,"claim":"Connected USP30 to the apoptotic threshold by showing TOM20 deubiquitylation and modulation of BAX/BAK-dependent cell death, extending its role beyond morphology.","evidence":"siRNA/shRNA depletion, TOM20 ubiquitylation assays, and BH3-mimetic sensitivity assays","pmids":["25739811"],"confidence":"Medium","gaps":["Molecular link between TOM20 deubiquitylation and BAX/BAK control not defined","Single-lab apoptosis phenotype"]},{"year":2017,"claim":"Provided the structural basis for USP30's Lys6-linkage preference and its inhibition by pSer65-ubiquitin, explaining substrate-chain selectivity and PINK1 cross-regulation.","evidence":"X-ray crystallography of mono- and Lys6-diubiquitin complexes, in vitro DUB assays, and Lys6-specific affimer pulldowns","pmids":["28945249"],"confidence":"High","gaps":["In vivo prevalence of Lys6 chains on substrates not quantified","Full substrate repertoire of Lys6 cleavage unknown"]},{"year":2018,"claim":"Revealed a dual-organelle role by showing peroxisomal USP30 suppresses basal pexophagy and acts upstream of PINK1 in basal mitophagy, broadening its quality-control scope.","evidence":"Mitophagy/pexophagy reporters, peroxisomal localization by fractionation/imaging, and genetic perturbation","pmids":["29895712"],"confidence":"High","gaps":["Peroxisomal substrates not identified in this study","Mechanism of dual targeting between organelles unclear"]},{"year":2018,"claim":"Identified DRP1 as a USP30 substrate recruited via GNPAT, linking USP30-driven fission to hepatocarcinogenesis.","evidence":"Co-IP, DRP1 ubiquitination and stability assays, and loss-of-function in HCC cells","pmids":["30143522"],"confidence":"Medium","gaps":["Reciprocal validation of GNPAT-USP30 complex limited","Chain linkage on DRP1 not defined"]},{"year":2019,"claim":"Defined a PEX2–USP30 ubiquitin axis controlling peroxisome abundance, establishing the E3 ligase USP30 opposes at peroxisomes.","evidence":"USP30 overexpression/depletion, pexophagy assays, peroxisomal imaging, and genetic epistasis with PEX2","pmids":["30700497"],"confidence":"High","gaps":["Specific PEX2-generated substrate chains not enumerated","Relative contribution of mitochondrial vs peroxisomal pools unresolved"]},{"year":2020,"claim":"Showed in physiological neurons that USP30 acts as a quality-control DUB at the TOM translocon, concentrating its effect on import substrates rather than the bulk Parkin target set.","evidence":"Quantitative ubiquitylomics in CRISPR USP30-/- iNeurons with mitophagy flux assays","pmids":["32142685"],"confidence":"High","gaps":["Modest mitophagy effect leaves physiological magnitude uncertain","Mechanism distinguishing translocon substrates unclear"]},{"year":2020,"claim":"Established that USP30 sets a trigger threshold by deubiquitylating TOM complex components to slow PINK1/Parkin amplification, with TOM20 ubiquitylation as a readout of USP30 loss.","evidence":"Selective inhibitor FT3967385 vs genetic KO comparison with proteomics and pS65-Ub kinetics in SH-SY5Y","pmids":["32636217"],"confidence":"High","gaps":["Threshold-setting model not tested in vivo","Quantitative kinetics of signal amplification not modeled"]},{"year":2020,"claim":"Mapped an active-site residue (W475) governing diubiquitin linkage selectivity, refining the determinants of K6-specificity.","evidence":"Genetic code expansion with noncanonical Trp analogues, in vitro diubiquitin DUB assays, and crystallography","pmids":["32484330"],"confidence":"Medium","gaps":["Engineered residues not physiological","Effect on cellular substrate selection untested"]},{"year":2021,"claim":"Extended USP30 substrates to NLRP3, linking it to inflammasome activation outside the mitophagy axis.","evidence":"Co-IP, ubiquitination assays, shRNA and inhibitor MF-094 with inflammasome readouts in skin fibroblasts","pmids":["34883112"],"confidence":"Medium","gaps":["Single-lab substrate claim","Chain type and direct enzymatic action not fully defined"]},{"year":2022,"claim":"Identified an autoinhibitory allosteric role for the transmembrane domain, proposing a regulatory mechanism for USP30 catalytic activity.","evidence":"Q14 peptide binding by fluorescence polarization and microscale thermophoresis with mitophagy and LIR-motif characterization","pmids":["34989313"],"confidence":"Medium","gaps":["Allosteric mechanism inferred rather than structurally proven","Physiological relevance of TM autoinhibition untested"]},{"year":2023,"claim":"Showed USP30 stabilizes Snail via K48-chain removal to promote EMT, adding a non-mitochondrial oncogenic substrate.","evidence":"Co-IP, ubiquitination assays, knockdown/overexpression with invasion assays in breast cancer cells","pmids":["38146008"],"confidence":"Medium","gaps":["Nuclear/cytosolic site of Snail deubiquitylation unclear given USP30 membrane anchoring","Single-lab claim"]},{"year":2023,"claim":"Defined a benzosulfonamide inhibitor binding mode in the thumb-palm cleft that blocks ubiquitin guidance rather than occluding the active site, informing inhibitor design.","evidence":"ABPP MS selectivity, enzyme kinetics, HDX-MS, and computational docking","pmids":["37385347"],"confidence":"High","gaps":["Cellular efficacy correlation not central to this study","Docking-inferred rearrangements not crystallographically confirmed here"]},{"year":2024,"claim":"Identified a CDK5-USP30 phosphorylation axis (Ser216) that stabilizes USP30 and suppresses mitophagy while activating MAVS inflammation in Parkinson's disease models.","evidence":"Ser216 site mapping, CDK5 inhibition, stability assays, and MPTP/MPP+ models in BV2 cells and mice","pmids":["38772138"],"confidence":"Medium","gaps":["Direct CDK5 kinase action on USP30 vs indirect effect not fully separated","Single-lab in vivo model"]},{"year":2024,"claim":"Expanded the metabolic and cancer substrate set by showing USP30 stabilizes FTO (serine sensing), C/EBPβ (via NPRC), TOMM40, and S100A6 (via HMGA2).","evidence":"Co-IP, ubiquitination assays, domain mapping, mass spectrometry, and metabolic/proliferation readouts across cancer and metabolic models","pmids":["41652187","39433172","40227042","39694080"],"confidence":"Medium","gaps":["Several are single-lab substrate claims with limited orthogonal validation","How a membrane DUB accesses these substrates not resolved"]},{"year":2025,"claim":"Provided structural and mechanistic detail on specific inhibitor engagement, including a cryptic pocket from switching-loop rearrangement and a covalent inhibitor near catalytic Cys77.","evidence":"Crystallography of chimeric USP30-inhibitor complex and HDX-MS/ABPP with covalent inhibitor USP30-I-1","pmids":["40325251","39804742"],"confidence":"High","gaps":["In vivo selectivity and pharmacology not addressed structurally","Differential clinical relevance of binding modes unknown"]},{"year":2025,"claim":"Demonstrated mitophagy-independent functions: USP30 stabilizes HK1/HK2 to drive glycolysis and stabilizes MAT2A to maintain endothelial barrier function, and its loss improves mitochondrial efficiency independently of PINK1/Parkin.","evidence":"Ubiquitinomics with K144R mutagenesis and HK activity assays; EC-specific USP30 KO mice with SAM/methylation readouts; genetic and pharmacological perturbation with bioenergetic assays (one preprint)","pmids":["41688443","41104980"],"confidence":"High","gaps":["Breadth of PINK1/Parkin-independent functions not unified","Mechanism of substrate access for soluble metabolic enzymes unclear"]},{"year":null,"claim":"How USP30 substrate selection is partitioned between its TOM-complex quality-control role and the growing list of non-mitochondrial substrates, and how its localization permits access to cytosolic/nuclear targets, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model reconciling membrane anchoring with non-mitochondrial substrates","Physiological hierarchy among substrates unknown","Several candidate substrates rest on single-lab Co-IP evidence"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,3,4,8,22]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,4,13]}],"localization":[{"term_id":"GO:0005777","term_label":"peroxisome","supporting_discovery_ids":[5,7]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,1,8]}],"pathway":[{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[1,5,7,9]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[0,2,5]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[4,8,22]}],"complexes":[],"partners":["TOMM20","TOMM40","MFN1","MFN2","DNM1L","PEX2","HK2","GNPAT"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q70CQ3","full_name":"Ubiquitin carboxyl-terminal hydrolase 30","aliases":["Deubiquitinating enzyme 30","Ubiquitin thioesterase 30","Ubiquitin-specific-processing protease 30","Ub-specific protease 30"],"length_aa":517,"mass_kda":58.5,"function":"Deubiquitinating enzyme tethered to the mitochondrial outer membrane that acts as a key inhibitor of mitophagy by counteracting the action of parkin (PRKN): hydrolyzes ubiquitin attached by parkin on target proteins, such as RHOT1/MIRO1 and TOMM20, thereby blocking parkin's ability to drive mitophagy (PubMed:18287522, PubMed:24896179, PubMed:25527291, PubMed:25621951). Preferentially cleaves 'Lys-6'- and 'Lys-11'-linked polyubiquitin chains, 2 types of linkage that participate in mitophagic signaling (PubMed:25621951). Does not cleave efficiently polyubiquitin phosphorylated at 'Ser-65' (PubMed:25527291). Acts as a negative regulator of mitochondrial fusion by mediating deubiquitination of MFN1 and MFN2 (By similarity)","subcellular_location":"Mitochondrion outer membrane","url":"https://www.uniprot.org/uniprotkb/Q70CQ3/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/USP30","classification":"Not Classified","n_dependent_lines":26,"n_total_lines":1208,"dependency_fraction":0.02152317880794702},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/USP30","total_profiled":1310},"omim":[{"mim_id":"612492","title":"UBIQUITIN-SPECIFIC PROTEASE 30; USP30","url":"https://www.omim.org/entry/612492"},{"mim_id":"608309","title":"PTEN-INDUCED KINASE 1; PINK1","url":"https://www.omim.org/entry/608309"},{"mim_id":"602544","title":"PARKIN RBR E3 UBIQUITIN PROTEIN LIGASE; PRKN","url":"https://www.omim.org/entry/602544"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/USP30"},"hgnc":{"alias_symbol":["MGC10702","FLJ40511"],"prev_symbol":[]},"alphafold":{"accession":"Q70CQ3","domains":[{"cath_id":"3.90.70.10","chopping":"68-178_433-506","consensus_level":"high","plddt":90.9931,"start":68,"end":506},{"cath_id":"-","chopping":"228-248_264-294_302-317","consensus_level":"medium","plddt":95.5607,"start":228,"end":317},{"cath_id":"1.20.5","chopping":"15-53","consensus_level":"medium","plddt":71.7626,"start":15,"end":53}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q70CQ3","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q70CQ3-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q70CQ3-F1-predicted_aligned_error_v6.png","plddt_mean":76.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=USP30","jax_strain_url":"https://www.jax.org/strain/search?query=USP30"},"sequence":{"accession":"Q70CQ3","fasta_url":"https://rest.uniprot.org/uniprotkb/Q70CQ3.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q70CQ3/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q70CQ3"}},"corpus_meta":[{"pmid":"24896179","id":"PMC_24896179","title":"The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy.","date":"2014","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/24896179","citation_count":690,"is_preprint":false},{"pmid":"27094585","id":"PMC_27094585","title":"Mechanisms of mitophagy: PINK1, Parkin, USP30 and beyond.","date":"2016","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27094585","citation_count":265,"is_preprint":false},{"pmid":"24513856","id":"PMC_24513856","title":"A small natural molecule promotes mitochondrial fusion through inhibition of the deubiquitinase USP30.","date":"2014","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/24513856","citation_count":179,"is_preprint":false},{"pmid":"28945249","id":"PMC_28945249","title":"Mechanism and regulation of the Lys6-selective deubiquitinase USP30.","date":"2017","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28945249","citation_count":178,"is_preprint":false},{"pmid":"32142685","id":"PMC_32142685","title":"Global Landscape and Dynamics of Parkin and USP30-Dependent Ubiquitylomes in iNeurons during Mitophagic Signaling.","date":"2020","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/32142685","citation_count":169,"is_preprint":false},{"pmid":"18287522","id":"PMC_18287522","title":"Regulation of mitochondrial morphology by USP30, a deubiquitinating enzyme present in the mitochondrial outer membrane.","date":"2008","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/18287522","citation_count":145,"is_preprint":false},{"pmid":"25739811","id":"PMC_25739811","title":"USP30 deubiquitylates mitochondrial Parkin substrates and restricts apoptotic cell death.","date":"2015","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/25739811","citation_count":140,"is_preprint":false},{"pmid":"29895712","id":"PMC_29895712","title":"Dual role of USP30 in controlling basal pexophagy and mitophagy.","date":"2018","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/29895712","citation_count":132,"is_preprint":false},{"pmid":"32636217","id":"PMC_32636217","title":"USP30 sets a trigger threshold for PINK1-PARKIN amplification of mitochondrial ubiquitylation.","date":"2020","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/32636217","citation_count":101,"is_preprint":false},{"pmid":"29935771","id":"PMC_29935771","title":"Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy.","date":"2018","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/29935771","citation_count":101,"is_preprint":false},{"pmid":"37957154","id":"PMC_37957154","title":"Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's disease mouse model.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37957154","citation_count":70,"is_preprint":false},{"pmid":"30700497","id":"PMC_30700497","title":"Deubiquitinating enzyme USP30 maintains basal peroxisome abundance by regulating pexophagy.","date":"2019","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/30700497","citation_count":59,"is_preprint":false},{"pmid":"30143522","id":"PMC_30143522","title":"Amplification of Glyceronephosphate O-Acyltransferase and Recruitment of USP30 Stabilize DRP1 to Promote Hepatocarcinogenesis.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30143522","citation_count":54,"is_preprint":false},{"pmid":"34844982","id":"PMC_34844982","title":"Benchmarking a highly selective USP30 inhibitor for enhancement of mitophagy and pexophagy.","date":"2021","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/34844982","citation_count":49,"is_preprint":false},{"pmid":"34704599","id":"PMC_34704599","title":"Investigation of USP30 inhibition to enhance Parkin-mediated mitophagy: tools and approaches.","date":"2021","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/34704599","citation_count":44,"is_preprint":false},{"pmid":"34989313","id":"PMC_34989313","title":"Identification of an autoinhibitory, mitophagy-inducing peptide derived from the transmembrane domain of USP30.","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/34989313","citation_count":43,"is_preprint":false},{"pmid":"35308234","id":"PMC_35308234","title":"USP30: Structure, Emerging Physiological Role, and Target Inhibition.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35308234","citation_count":42,"is_preprint":false},{"pmid":"33890401","id":"PMC_33890401","title":"Pharmacological inhibition of USP30 activates tissue-specific mitophagy.","date":"2021","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/33890401","citation_count":40,"is_preprint":false},{"pmid":"38225227","id":"PMC_38225227","title":"USP30 inhibition induces mitophagy and reduces oxidative stress in parkin-deficient human neurons.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38225227","citation_count":38,"is_preprint":false},{"pmid":"33986866","id":"PMC_33986866","title":"Long non-coding RNA USP30-AS1 aggravates the malignant progression of cervical cancer by sequestering microRNA-299-3p and thereby overexpressing PTP4A1.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/33986866","citation_count":35,"is_preprint":false},{"pmid":"38147294","id":"PMC_38147294","title":"Inhibition of USP30 Promotes Mitophagy by Regulating Ubiquitination of MFN2 by Parkin to Attenuate Early Brain Injury After SAH.","date":"2023","source":"Translational stroke research","url":"https://pubmed.ncbi.nlm.nih.gov/38147294","citation_count":33,"is_preprint":false},{"pmid":"34883112","id":"PMC_34883112","title":"MF-094, a potent and selective USP30 inhibitor, accelerates diabetic wound healing by inhibiting the NLRP3 inflammasome.","date":"2021","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/34883112","citation_count":30,"is_preprint":false},{"pmid":"34694569","id":"PMC_34694569","title":"LncRNA USP30-AS1 promotes the survival of acute myeloid leukemia cells by cis-regulating USP30 and ANKRD13A.","date":"2021","source":"Human cell","url":"https://pubmed.ncbi.nlm.nih.gov/34694569","citation_count":26,"is_preprint":false},{"pmid":"37385347","id":"PMC_37385347","title":"Structural Premise of Selective Deubiquitinase USP30 Inhibition by Small-Molecule Benzosulfonamides.","date":"2023","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/37385347","citation_count":25,"is_preprint":false},{"pmid":"34653676","id":"PMC_34653676","title":"USP30-AS1 contributes to mitochondrial quality control in glioblastoma cells.","date":"2021","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/34653676","citation_count":25,"is_preprint":false},{"pmid":"33609088","id":"PMC_33609088","title":"USP30 protects against oxygen-glucose deprivation/reperfusion induced mitochondrial fragmentation and ubiquitination and degradation of MFN2.","date":"2021","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/33609088","citation_count":24,"is_preprint":false},{"pmid":"29178074","id":"PMC_29178074","title":"Beyond Deubiquitylation: USP30-Mediated Regulation of Mitochondrial Homeostasis.","date":"2017","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/29178074","citation_count":21,"is_preprint":false},{"pmid":"35260141","id":"PMC_35260141","title":"lncRNA USP30-AS1 sponges miR-765 and modulates the progression of colon cancer.","date":"2022","source":"World journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35260141","citation_count":20,"is_preprint":false},{"pmid":"34290230","id":"PMC_34290230","title":"Deubiquitinating enzyme USP30 negatively regulates mitophagy and accelerates myocardial cell senescence through antagonism of Parkin.","date":"2021","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/34290230","citation_count":17,"is_preprint":false},{"pmid":"36474192","id":"PMC_36474192","title":"MF-094 nanodelivery inhibits oral squamous cell carcinoma by targeting USP30.","date":"2022","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/36474192","citation_count":17,"is_preprint":false},{"pmid":"34381024","id":"PMC_34381024","title":"Regulation of Bax-dependent apoptosis by mitochondrial deubiquitinase USP30.","date":"2021","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/34381024","citation_count":17,"is_preprint":false},{"pmid":"35417128","id":"PMC_35417128","title":"Novel Imidazole Phenoxyacetic Acids as Inhibitors of USP30 for Neuroprotection Implication via the Ubiquitin-Rho-110 Fluorometric Assay: Design, Synthesis, and In Silico and Biochemical Assays.","date":"2022","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/35417128","citation_count":16,"is_preprint":false},{"pmid":"38146008","id":"PMC_38146008","title":"USP30 promotes the progression of breast cancer by stabilising Snail.","date":"2023","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38146008","citation_count":15,"is_preprint":false},{"pmid":"35250566","id":"PMC_35250566","title":"The Mitochondrial Deubiquitinase USP30 Regulates AKT/mTOR Signaling.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35250566","citation_count":14,"is_preprint":false},{"pmid":"40325251","id":"PMC_40325251","title":"Chimeric deubiquitinase engineering reveals structural basis for specific inhibition of the mitophagy regulator USP30.","date":"2025","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/40325251","citation_count":13,"is_preprint":false},{"pmid":"39777915","id":"PMC_39777915","title":"An interferon-stimulated long non-coding RNA USP30-AS1 as an immune modulator in influenza A virus infection.","date":"2025","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/39777915","citation_count":13,"is_preprint":false},{"pmid":"38163556","id":"PMC_38163556","title":"Chaihu Shugan Powder inhibits interstitial cells of cajal mitophagy through USP30 in the treatment of functional dyspepsia.","date":"2023","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38163556","citation_count":13,"is_preprint":false},{"pmid":"31356149","id":"PMC_31356149","title":"New aspects of USP30 biology in the regulation of pexophagy.","date":"2019","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/31356149","citation_count":11,"is_preprint":false},{"pmid":"38772138","id":"PMC_38772138","title":"CDK5-USP30 signaling pathway regulates MAVS-mediated inflammation via suppressing mitophagy in MPTP/MPP+ PD model.","date":"2024","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/38772138","citation_count":8,"is_preprint":false},{"pmid":"38725909","id":"PMC_38725909","title":"Discovery of potent and selective activity-based probes (ABPs) for the deubiquitinating enzyme USP30.","date":"2024","source":"RSC chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/38725909","citation_count":8,"is_preprint":false},{"pmid":"30086320","id":"PMC_30086320","title":"Organelle Turnover: A USP30 Safety Catch Restrains the Trigger for Mitophagy and Pexophagy.","date":"2018","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/30086320","citation_count":8,"is_preprint":false},{"pmid":"32484330","id":"PMC_32484330","title":"Probing the Active Site of Deubiquitinase USP30 with Noncanonical Tryptophan Analogues.","date":"2020","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32484330","citation_count":7,"is_preprint":false},{"pmid":"40815646","id":"PMC_40815646","title":"USP30 inhibition augments mitophagy to prevent T cell exhaustion.","date":"2025","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/40815646","citation_count":6,"is_preprint":false},{"pmid":"39433172","id":"PMC_39433172","title":"NPRC promotes hepatic steatosis via USP30-mediated deubiquitination of C/EBPβ.","date":"2024","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/39433172","citation_count":6,"is_preprint":false},{"pmid":"40020267","id":"PMC_40020267","title":"Long noncoding RNA USP30-AS1 promotes influenza A virus replication by enhancing PHB1 function.","date":"2025","source":"Veterinary microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/40020267","citation_count":6,"is_preprint":false},{"pmid":"39804742","id":"PMC_39804742","title":"Structural Dynamics of the Ubiquitin Specific Protease USP30 in Complex with a Cyanopyrrolidine-Containing Covalent Inhibitor.","date":"2025","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/39804742","citation_count":6,"is_preprint":false},{"pmid":"34743664","id":"PMC_34743664","title":"The intriguing role of USP30 inhibitors as deubiquitinating enzymes from the patent literature since 2013.","date":"2022","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/34743664","citation_count":5,"is_preprint":false},{"pmid":"31131315","id":"PMC_31131315","title":"USP30: protector of peroxisomes and mitochondria.","date":"2019","source":"Molecular & cellular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31131315","citation_count":5,"is_preprint":false},{"pmid":"39014929","id":"PMC_39014929","title":"Exosomal lncRNA USP30-AS1 activates the Wnt/β-catenin signaling pathway to promote cervical cancer progression via stabilization of β-catenin by USP30.","date":"2024","source":"Biotechnology journal","url":"https://pubmed.ncbi.nlm.nih.gov/39014929","citation_count":4,"is_preprint":false},{"pmid":"39601128","id":"PMC_39601128","title":"Modulation of OPC Mitochondrial Function by Inhibiting USP30 Promotes Their Differentiation.","date":"2024","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/39601128","citation_count":4,"is_preprint":false},{"pmid":"40918504","id":"PMC_40918504","title":"Spotlight on USP30: structure, function, disease and target inhibition.","date":"2025","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40918504","citation_count":3,"is_preprint":false},{"pmid":"39694080","id":"PMC_39694080","title":"FOXF1 promotes ovarian cancer metastasis by facilitating HMGA2-mediated USP30-dependent S100A6 deubiquitination.","date":"2024","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/39694080","citation_count":3,"is_preprint":false},{"pmid":"40227042","id":"PMC_40227042","title":"USP30 Aggravating the Malignant Progression of Breast Cancer and Its Resistance to Tamoxifen by Inhibiting the Ubiquitination of TOMM40.","date":"2025","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/40227042","citation_count":3,"is_preprint":false},{"pmid":"40709564","id":"PMC_40709564","title":"GNPAT/USP30 Stabilizes DRP1 Protein to Promote Mitochondrial Fission and Functional Damage in COPD Progression.","date":"2025","source":"The Kaohsiung journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40709564","citation_count":2,"is_preprint":false},{"pmid":"41104980","id":"PMC_41104980","title":"Activation of USP30 Disrupts Endothelial Cell Function and Aggravates Acute Lung Injury Through Regulating the S-Adenosylmethionine Cycle.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/41104980","citation_count":2,"is_preprint":false},{"pmid":"39503963","id":"PMC_39503963","title":"USP30-AS1 Suppresses Colon Cancer Cell Inflammatory Response Through NF-κB/MYBBP1A Signaling.","date":"2024","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/39503963","citation_count":2,"is_preprint":false},{"pmid":"39757210","id":"PMC_39757210","title":"The expression of the lncRNAs USP30-AS1, ELFN1-AS1, GAS8-AS1, and SNHG11 in breast cancer samples from Iranian patients from 2014 to 2019: a cross-sectional study.","date":"2025","source":"BMC research notes","url":"https://pubmed.ncbi.nlm.nih.gov/39757210","citation_count":2,"is_preprint":false},{"pmid":"41320325","id":"PMC_41320325","title":"USP30 Knockdown Drives Mitophagy and Suppresses Pyroptosis in Heart Failure by Activating the PINK1/Parkin Pathway.","date":"2025","source":"International heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/41320325","citation_count":1,"is_preprint":false},{"pmid":"41492473","id":"PMC_41492473","title":"Nuclear and cytoplasmic USP30-AS1 coordinately regulate breast cancer progression through HnRNPF/p21 and EZH2/c-Myc/p21 axes.","date":"2025","source":"Genes & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/41492473","citation_count":1,"is_preprint":false},{"pmid":"40274689","id":"PMC_40274689","title":"Structure-based discovery of novel non-covalent small molecule inhibitors of USP30.","date":"2025","source":"Journal of computer-aided molecular design","url":"https://pubmed.ncbi.nlm.nih.gov/40274689","citation_count":1,"is_preprint":false},{"pmid":"41652187","id":"PMC_41652187","title":"USP30 senses serine/glycine levels to regulate serine biosynthesis and colorectal tumorigenesis by deubiquitinating FTO.","date":"2026","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/41652187","citation_count":0,"is_preprint":false},{"pmid":"41614739","id":"PMC_41614739","title":"USP30-AS1 Dictates Breast Cancer Cell Fate and Chemoresistance via a miR-3646/FZD7/Wnt/β-Catenin Circuit.","date":"2025","source":"Current issues in molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/41614739","citation_count":0,"is_preprint":false},{"pmid":"41688443","id":"PMC_41688443","title":"USP30-mediated Deubiquitination of Hexokinase 2 controls the metabolic fate of glucose and tumor progression.","date":"2026","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/41688443","citation_count":0,"is_preprint":false},{"pmid":"41765114","id":"PMC_41765114","title":"USP30 alleviates intestinal ischemia-reperfusion injury by deubiquitinating MFN2 mediating the mitochondrial endoplasmic reticulum pathway.","date":"2026","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41765114","citation_count":0,"is_preprint":false},{"pmid":"41749253","id":"PMC_41749253","title":"USP30-AS1 functions as a post-transcriptional amplifier of interferon signalling to drive autoimmune pathogenesis.","date":"2026","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/41749253","citation_count":0,"is_preprint":false},{"pmid":"41587019","id":"PMC_41587019","title":"Targeting mitochondrial deubiquitinase USP30 to induce mitophagy in heteroplasmic mitochondrial diseases.","date":"2026","source":"Pharmacological reports : PR","url":"https://pubmed.ncbi.nlm.nih.gov/41587019","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.02.03.636341","title":"USP30 inhibition improves mitochondrial health through both PINK1-dependent and independent mechanisms","date":"2025-02-06","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.03.636341","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.22.613429","title":"Chimeric deubiquitinase engineering reveals structural basis for specific inhibition of USP30 and a framework for DUB ligandability","date":"2024-09-22","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.22.613429","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.07.616967","title":"Integrative Proximal-Ubiquitomics Profiling for Deubiquitinase and E3 Ligase Substrate Discovery Applied to USP30","date":"2024-10-08","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.07.616967","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.24.614749","title":"The p97-UBXD8 complex maintains peroxisome abundance by suppressing pexophagy","date":"2024-09-27","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.24.614749","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.30.621201","title":"Deficiency of mitophagy mediator Parkin in aortic smooth muscle cells exacerbates abdominal aortic aneurysm","date":"2024-11-01","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.30.621201","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":34584,"output_tokens":6461,"usd":0.100334,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15335,"output_tokens":5624,"usd":0.108637,"stage2_stop_reason":"end_turn"},"total_usd":0.208971,"stage1_batch_id":"msgbatch_01UT1AahFPCAyn2uVweS7A9z","stage2_batch_id":"msgbatch_01HuKWtKNT4Pqj1bc8eEP5RV","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"USP30 is a deubiquitinating enzyme embedded in the mitochondrial outer membrane; depletion by RNAi induces elongated, interconnected mitochondria dependent on mitofusin activity, and this phenotype is rescued by enzymatically active USP30 but not catalytic mutants, establishing USP30 as a regulator of mitochondrial morphology through its DUB activity.\",\n      \"method\": \"RNAi knockdown, ectopic expression of wild-type vs. catalytic-dead USP30, fluorescence microscopy of mitochondrial morphology, subcellular fractionation\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal loss-of-function and rescue with catalytic mutant, single lab, two orthogonal methods (RNAi + overexpression with mutagenesis)\",\n      \"pmids\": [\"18287522\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"USP30 localizes to mitochondria and opposes Parkin-mediated mitophagy: overexpression of USP30 removes ubiquitin from Parkin substrates on damaged mitochondria and blocks mitophagy, while USP30 knockdown enhances mitochondrial degradation. Global ubiquitination site profiling identified multiple mitochondrial substrates oppositely regulated by Parkin and USP30. In Drosophila, USP30 knockdown rescues defective mitophagy caused by pathogenic Parkin mutations and protects dopaminergic neurons against paraquat toxicity.\",\n      \"method\": \"Overexpression/knockdown, global ubiquitination site profiling (mass spectrometry), mitophagy assays, Drosophila genetic rescue experiments\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (proteomics, cell biology, in vivo genetics), replicated across cell and animal models\",\n      \"pmids\": [\"24896179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The diterpenoid derivative 15-oxospiramilactone (S3) inhibits USP30, leading to non-degradative ubiquitination of Mfn1/2 that enhances mitofusin activity and promotes mitochondrial fusion, uncovering that USP30-dependent deubiquitination of mitofusins suppresses their fusion activity.\",\n      \"method\": \"Chemical inhibition with S3, mitochondrial fusion assays, ubiquitination assays for Mfn1/2, cell lines deficient in Mfn1 or Mfn2\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional rescue with inhibitor and genetic target identification, single lab, two orthogonal methods\",\n      \"pmids\": [\"24513856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"USP30 deubiquitylates TOM20 opposing Parkin-dependent ubiquitylation; USP30 depletion enhances depolarization-induced cell death in Parkin-overexpressing cells and sensitizes cancer cells to BH3-mimetics by regulating BAX/BAK-dependent apoptosis, establishing a role for USP30 in controlling the mitochondrial apoptotic threshold.\",\n      \"method\": \"USP30 depletion (siRNA/shRNA), cell death assays, ubiquitylation assays for TOM20, BH3-mimetic sensitivity assays\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined apoptotic phenotype and substrate identification, single lab, two orthogonal methods\",\n      \"pmids\": [\"25739811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Crystal structures of human USP30 bound to monoubiquitin and Lys6-linked diubiquitin reveal unique ubiquitin-binding interfaces that confer Lys6-linkage preference for cleavage. Distally phosphorylated (pSer65) ubiquitin chains impair USP30 activity. Lys6-linkage-specific affimers identified TOM20 as a mitochondrial substrate for Lys6-polyubiquitination regulated by USP30.\",\n      \"method\": \"X-ray crystallography, in vitro DUB activity assays, phospho-ubiquitin chain inhibition assays, Lys6-specific affimer pulldowns, quantitative proteomics\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures with functional validation (activity assays, mutagenesis-informed substrate identification, multiple orthogonal methods)\",\n      \"pmids\": [\"28945249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"USP30 regulates basal pexophagy independently of PINK1 and Parkin: a fraction of endogenous USP30 localizes to peroxisomes where it suppresses basal pexophagy. Additionally, USP30 acts upstream of PINK1 in basal mitophagy by modulating PINK1-substrate availability, establishing dual organelle roles.\",\n      \"method\": \"Mitophagy reporter systems, immunofluorescence/fractionation to show peroxisomal localization, genetic KO/knockdown of USP30, PINK1 pathway analysis\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent mitophagy reporter systems, localization experiments, genetic perturbations, replicated with two distinct assays\",\n      \"pmids\": [\"29895712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GNPAT recruits USP30, which deubiquitylates and stabilizes DRP1, thereby promoting mitochondrial fission and hepatocarcinogenesis; USP30 interaction with DRP1 was established by Co-IP.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, DRP1 protein stability assays, loss-of-function experiments in HCC cells\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP and ubiquitination assay, single lab, two orthogonal methods identifying substrate\",\n      \"pmids\": [\"30143522\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"USP30 localizes to peroxisomes and prevents pexophagy by counteracting the peroxisomal E3 ubiquitin ligase PEX2; USP30 overexpression blocks amino-acid-starvation-induced pexophagy, and its depletion triggers basal pexophagy, establishing a PEX2–USP30 ubiquitin axis controlling peroxisome abundance.\",\n      \"method\": \"USP30 overexpression/depletion, pexophagy assays, peroxisomal localization by microscopy, genetic epistasis with PEX2\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (PEX2/USP30), direct localization, functional pexophagy assays, replicates prior localization finding from different lab\",\n      \"pmids\": [\"30700497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In induced neurons (iNeurons), USP30 knockout reveals that elevated ubiquitylation targets concentrate on mitochondrial translocon (TOM complex) components; USP30 loss accelerates pS65-Ub accumulation and mitophagic flux modestly without altering ubiquitylation kinetics of the vast majority of Parkin targets. Basally, ubiquitylated translocon import substrates accumulate in USP30-/- iNeurons, indicating a quality control function for USP30 at the TOM complex.\",\n      \"method\": \"Quantitative ubiquitylomics/proteomics in USP30-/- iNeurons, CRISPR KO, mitophagy flux assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — quantitative proteomics with genetic KO in physiologically relevant neuronal model, multiple orthogonal methods, independent of prior studies\",\n      \"pmids\": [\"32142685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"USP30 sets a trigger threshold for PINK1-Parkin amplification of mitochondrial ubiquitylation: TOM20 ubiquitylation is a robust biomarker for USP30 loss/inhibition, and USP30 deubiquitylation of TOM complex components dampens the local ubiquitin signal at the site of PINK1 accumulation following depolarization, slowing Parkin-dependent amplification.\",\n      \"method\": \"Selective USP30 inhibitor (FT3967385), proteomics in SH-SY5Y cells, comparison of genetic KO vs chemical inhibition, pS65-Ub kinetics, mitophagy assays\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — chemical inhibitor vs. genetic KO comparison with quantitative proteomics, defines mechanistic model with multiple orthogonal readouts\",\n      \"pmids\": [\"32636217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Tryptophan residue W475 near the USP30 active site contributes to diubiquitin linkage selectivity; replacement with noncanonical Trp analogues modulates activity and K6-specificity, with 3-benzothienyl-l-alanine inducing unique K6-specificity.\",\n      \"method\": \"Genetic code expansion/noncanonical amino acid incorporation, in vitro DUB activity assays with diubiquitin substrates, X-ray crystallography of PylRS-ncAA complexes\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro mutagenesis with noncanonical residues and structural data, single lab, novel mechanistic insight into active site\",\n      \"pmids\": [\"32484330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"USP30 deubiquitylates NLRP3, activating the NLRP3 inflammasome; this interaction was verified by Co-IP and ubiquitination assays, and USP30 knockdown or inhibition reduces NLRP3 inflammasome activity in skin fibroblasts.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, shRNA knockdown, USP30 inhibitor MF-094, NLRP3 inflammasome activity readouts\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP plus ubiquitination assay, single lab, two orthogonal methods identifying novel substrate\",\n      \"pmids\": [\"34883112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A peptide (Q14) derived from the transmembrane domain of USP30 inhibits USP30 via an autoinhibitory allosteric mechanism; binding sites between Q14 and USP30 were identified by fluorescence polarization and microscale thermophoresis, proposing that the TM domain can allosterically regulate USP30 catalytic activity.\",\n      \"method\": \"Fluorescence polarization, microscale thermophoresis, peptide binding studies, mitophagy assays, LC3-interaction via LIR motif characterization\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — binding assays with functional readout, single lab, two orthogonal binding methods but allosteric mechanism inferred rather than directly structurally proven\",\n      \"pmids\": [\"34989313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A benzosulfonamide inhibitor (USP30inh) binds to the cleft between the USP30 thumb and palm subdomains, preventing ubiquitin C-terminus guidance to the active site; hydrogen-deuterium exchange MS and computational docking reveal compound-induced structural rearrangements at this cleft rather than direct active-site occlusion.\",\n      \"method\": \"Activity-based protein profiling MS (selectivity against 49 DUBs), enzyme kinetics, hydrogen-deuterium exchange MS, computational docking\",\n      \"journal\": \"Molecular & cellular proteomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple structural/biochemical methods (HDX-MS, kinetics, ABPP) in single rigorous study defining inhibitor binding mode\",\n      \"pmids\": [\"37385347\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"USP30 interacts with and deubiquitylates Snail via K48-linked polyubiquitin chains, stabilizing Snail protein and promoting EMT in breast cancer cells; verified by Co-IP and ubiquitination assays.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, knockdown/overexpression, proliferation/invasion assays\",\n      \"journal\": \"Cancer gene therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP and ubiquitination assay, single lab, two orthogonal methods identifying novel non-mitochondrial substrate\",\n      \"pmids\": [\"38146008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CDK5 phosphorylates USP30 at serine 216 to stabilize USP30 protein; CDK5-USP30 signaling suppresses mitophagy and activates MAVS-mediated inflammation in MPTP/MPP+-induced Parkinson's disease models.\",\n      \"method\": \"Phosphorylation site identification (Ser216), CDK5 inhibition experiments, USP30 protein stability assays, MAVS pathway analysis, mitophagy assays in BV2 cells and in vivo MPTP mouse model\",\n      \"journal\": \"Ecotoxicology and environmental safety\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — phosphorylation site mapped and functional consequence shown, single lab, in vitro and in vivo evidence\",\n      \"pmids\": [\"38772138\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NPRC recruits USP30 to deubiquitinate C/EBPβ at K149 (K48-linked polyubiquitination), stabilizing C/EBPβ and driving lipid metabolism reprogramming in MAFLD; the DNA-binding domain of C/EBPβ interacts with USP30, and the ANPR region of NPRC binds USP30.\",\n      \"method\": \"Proteomics, ubiquitination analysis, Co-immunoprecipitation, domain mapping experiments\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP and ubiquitination site mapping, single lab, two orthogonal methods identifying novel substrate and regulatory complex\",\n      \"pmids\": [\"39433172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"HMGA2 stabilizes S100A6 by recruiting USP30, inhibiting S100A6 ubiquitination/degradation; demonstrated by Co-IP and mass spectrometry in ovarian cancer cells.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, ubiquitination assays, rescue experiments\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP/MS study, single lab, novel substrate claim with limited mechanistic follow-up\",\n      \"pmids\": [\"39694080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"USP30 binds to and deubiquitylates FTO, protecting it from proteasomal degradation; USP30 senses serine/glycine levels to regulate FTO stability, which in turn demethylates PHGDH/PSAT1 mRNAs promoting serine biosynthesis in colorectal cancer.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, proteomic/metabolomic analyses, m6A demethylation assays\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP and ubiquitination assays identifying novel substrate and metabolite-sensing function, single lab, multiple orthogonal metabolic readouts\",\n      \"pmids\": [\"41652187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"USP30 deubiquitylates TOMM40, reducing its ubiquitination and stabilizing it; USP30 knockdown reduces TOMM40 protein levels and suppresses breast cancer cell proliferation and angiogenesis, establishing TOMM40 as a USP30 substrate in cancer.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, knockdown experiments, cell proliferation/angiogenesis assays\",\n      \"journal\": \"Journal of biochemical and molecular toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP and ubiquitination assay, single lab, two orthogonal methods\",\n      \"pmids\": [\"40227042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Crystal structure of human USP30 in complex with a specific inhibitor (enabled by chimeric protein engineering) reveals that the inhibitor occupies a cryptic pocket induced by a compound-driven conformation of the USP30 switching loop; the Leu73 ubiquitin-binding site constitutes a common ligandability hotspot for USP deubiquitinases.\",\n      \"method\": \"X-ray crystallography of chimeric USP30–inhibitor complex, chimeric protein engineering strategy, structure-activity relationship analysis\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with compound-induced conformational analysis, peer-reviewed, mechanistically validates cryptic pocket and identifies specific inhibitor binding residues\",\n      \"pmids\": [\"40325251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"A cyanopyrrolidine-containing covalent inhibitor (USP30-I-1) binds tightly near the catalytic cysteine (Cys77) of USP30 in a pocket along the thumb and palm domains, preventing ubiquitin substrate binding; HDX-MS reveals structural rearrangements that differ slightly from the benzosulfonamide binding mode, providing molecular basis for differential selectivity.\",\n      \"method\": \"Enzyme kinetics, hydrogen-deuterium exchange MS, activity-based protein profiling, selectivity profiling against DUB panel\",\n      \"journal\": \"Journal of proteome research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple structural/biochemical methods (HDX-MS, kinetics, ABPP) in single study with rigorous selectivity profiling\",\n      \"pmids\": [\"39804742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"USP30 deubiquitylates and stabilizes HK1 and HK2 by preferentially removing atypical ubiquitin chains; Lys144 of HK2 is the critical regulatory site, and USP30-mediated deubiquitination enhances HK2 stability, mitochondrial localization, VDAC1 binding, and hexokinase activity to promote glycolysis and tumor progression.\",\n      \"method\": \"Co-immunoprecipitation, quantitative proteomics and ubiquitinomics, site-directed mutagenesis (K144R), HK2 activity assays, mitochondrial fractionation\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution approach with mutagenesis at defined substrate lysine, quantitative ubiquitinomics, in vitro enzyme activity, multiple orthogonal methods in single study\",\n      \"pmids\": [\"41688443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"USP30 depletion destabilizes methionine adenosyltransferase 2A (MAT2A) through a deubiquitination-dependent mechanism, lowering SAM levels, reducing global DNA methylation, and upregulating miR-30a-5p to suppress MDM2 and NFAT5, thereby maintaining endothelial cell barrier function via a mitophagy-independent pathway.\",\n      \"method\": \"EC-specific USP30 knockout mice, LPS/ischemia-reperfusion lung injury models, ubiquitination assays for MAT2A, SAM level measurement, DNA methylation assays, miRNA expression\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic model plus multiple orthogonal biochemical readouts, single lab, novel mitophagy-independent substrate/pathway\",\n      \"pmids\": [\"41104980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"USP30 loss or pharmacological inhibition improves mitochondrial morphology, increases membrane potential and ATP levels with decreased oxygen consumption (suggesting more efficient mitochondrial network), and these morphological changes are independent of PINK1 or Parkin.\",\n      \"method\": \"CRISPR/Cas9 KO, CRISPRi knockdown, pharmacological inhibition, mitophagy reporters, electrophysiology, mitochondrial membrane potential and ATP assays in cell lines and iPSC-derived neurons\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic and pharmacological approaches with functional readouts, preprint, PINK1/Parkin independence established by epistasis\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Proximity-labelling ubiquitomics (APEX2 + K-ε-GG enrichment) identifies TOMM20, FKBP8, and LETM1 as USP30-proximal substrates; LETM1 is deubiquitinated in a USP30-dependent manner as a previously undescribed candidate substrate.\",\n      \"method\": \"APEX2 proximity labelling, ubiquitin remnant (K-ε-GG) enrichment, quantitative mass spectrometry, USP30 inhibition\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab preprint, proximity labelling identifies candidate substrates but direct deubiquitination of LETM1 not yet fully validated by orthogonal methods\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"USP30 is a mitochondrial outer membrane-anchored deubiquitinase (also present on peroxisomes) that preferentially cleaves Lys6-linked polyubiquitin chains—a selectivity explained by its crystal structure—and opposes PINK1/Parkin-driven mitophagy by removing ubiquitin from substrates including TOM20, TOM complex components, Mfn1/2, DRP1, and HK1/2; it also regulates pexophagy by counteracting PEX2-dependent ubiquitination, controls the apoptotic threshold via BAX/BAK, and engages additional substrates (Snail, FTO, NLRP3, MAT2A) in non-mitochondrial contexts, with its activity dampened by pSer65-ubiquitin chains generated by PINK1 and positively regulated by CDK5-mediated phosphorylation at Ser216.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"USP30 is a mitochondrial outer membrane-anchored deubiquitinase that regulates mitochondrial morphology and quality control by reversing ubiquitin signals on outer-membrane proteins [#0, #1]. It opposes PINK1/Parkin-driven mitophagy: USP30 removes ubiquitin from Parkin substrates on damaged mitochondria and blocks their degradation, while its loss enhances mitophagic flux and rescues defective mitophagy in Drosophila Parkin mutants [#1]. Mechanistically, USP30 deubiquitylates components of the TOM translocon, including TOM20 and TOMM40, thereby dampening the local ubiquitin signal at sites of PINK1 accumulation and setting a trigger threshold for Parkin-dependent amplification [#3, #9]; in neurons its loss causes ubiquitylated translocon import substrates to accumulate, defining a quality-control function at the TOM complex [#8]. Crystal structures of USP30 bound to monoubiquitin and Lys6-linked diubiquitin reveal ubiquitin-binding interfaces that confer Lys6-linkage cleavage preference, and distally pSer65-phosphorylated ubiquitin chains impair USP30 activity [#4]. Beyond translocon control, USP30 deubiquitylates and tunes the activity or stability of mitochondrial dynamics factors (Mfn1/2, DRP1), regulates the BAX/BAK-dependent apoptotic threshold, and counteracts the peroxisomal E3 ligase PEX2 to suppress basal pexophagy, giving it a dual organelle role [#2, #3, #6, #7]. CDK5 phosphorylates USP30 at Ser216 to stabilize the protein and suppress mitophagy [#15]. In non-mitochondrial contexts USP30 stabilizes additional substrates including Snail, FTO, MAT2A, NLRP3 and HK1/2 to influence EMT, serine biosynthesis, methylation, inflammasome activity and glycolysis [#11, #14, #18, #22, #23]. USP30 is an actively pursued drug target, with multiple inhibitor classes mapped to distinct binding modes near the catalytic and ubiquitin-binding sites [#13, #20, #21].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"Established that USP30 is an outer-membrane deubiquitinase whose catalytic activity controls mitochondrial morphology, answering what cellular process this DUB governs.\",\n      \"evidence\": \"RNAi knockdown with wild-type vs catalytic-dead rescue and mitochondrial morphology imaging\",\n      \"pmids\": [\"18287522\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrates mediating the morphology phenotype not identified\", \"Link to mitophagy not yet established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined USP30 as an antagonist of Parkin-mediated mitophagy and identified mitochondrial substrates oppositely regulated by Parkin, explaining how it counteracts mitochondrial clearance.\",\n      \"evidence\": \"Overexpression/knockdown, global ubiquitination site proteomics, and Drosophila genetic rescue of pathogenic Parkin mutants\",\n      \"pmids\": [\"24896179\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Linkage specificity of cleaved chains not yet resolved\", \"Direct vs indirect deubiquitylation of each profiled substrate unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed that USP30 deubiquitylation of mitofusins suppresses their fusion activity, mechanistically connecting USP30 to mitochondrial fusion.\",\n      \"evidence\": \"Chemical inhibition by 15-oxospiramilactone with Mfn1/2 ubiquitination and fusion assays in Mfn-deficient lines\",\n      \"pmids\": [\"24513856\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Inhibitor selectivity beyond USP30 not fully excluded\", \"Direct enzymatic action on Mfn chains not reconstituted\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connected USP30 to the apoptotic threshold by showing TOM20 deubiquitylation and modulation of BAX/BAK-dependent cell death, extending its role beyond morphology.\",\n      \"evidence\": \"siRNA/shRNA depletion, TOM20 ubiquitylation assays, and BH3-mimetic sensitivity assays\",\n      \"pmids\": [\"25739811\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular link between TOM20 deubiquitylation and BAX/BAK control not defined\", \"Single-lab apoptosis phenotype\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Provided the structural basis for USP30's Lys6-linkage preference and its inhibition by pSer65-ubiquitin, explaining substrate-chain selectivity and PINK1 cross-regulation.\",\n      \"evidence\": \"X-ray crystallography of mono- and Lys6-diubiquitin complexes, in vitro DUB assays, and Lys6-specific affimer pulldowns\",\n      \"pmids\": [\"28945249\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo prevalence of Lys6 chains on substrates not quantified\", \"Full substrate repertoire of Lys6 cleavage unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Revealed a dual-organelle role by showing peroxisomal USP30 suppresses basal pexophagy and acts upstream of PINK1 in basal mitophagy, broadening its quality-control scope.\",\n      \"evidence\": \"Mitophagy/pexophagy reporters, peroxisomal localization by fractionation/imaging, and genetic perturbation\",\n      \"pmids\": [\"29895712\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Peroxisomal substrates not identified in this study\", \"Mechanism of dual targeting between organelles unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified DRP1 as a USP30 substrate recruited via GNPAT, linking USP30-driven fission to hepatocarcinogenesis.\",\n      \"evidence\": \"Co-IP, DRP1 ubiquitination and stability assays, and loss-of-function in HCC cells\",\n      \"pmids\": [\"30143522\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reciprocal validation of GNPAT-USP30 complex limited\", \"Chain linkage on DRP1 not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined a PEX2–USP30 ubiquitin axis controlling peroxisome abundance, establishing the E3 ligase USP30 opposes at peroxisomes.\",\n      \"evidence\": \"USP30 overexpression/depletion, pexophagy assays, peroxisomal imaging, and genetic epistasis with PEX2\",\n      \"pmids\": [\"30700497\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific PEX2-generated substrate chains not enumerated\", \"Relative contribution of mitochondrial vs peroxisomal pools unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed in physiological neurons that USP30 acts as a quality-control DUB at the TOM translocon, concentrating its effect on import substrates rather than the bulk Parkin target set.\",\n      \"evidence\": \"Quantitative ubiquitylomics in CRISPR USP30-/- iNeurons with mitophagy flux assays\",\n      \"pmids\": [\"32142685\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Modest mitophagy effect leaves physiological magnitude uncertain\", \"Mechanism distinguishing translocon substrates unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established that USP30 sets a trigger threshold by deubiquitylating TOM complex components to slow PINK1/Parkin amplification, with TOM20 ubiquitylation as a readout of USP30 loss.\",\n      \"evidence\": \"Selective inhibitor FT3967385 vs genetic KO comparison with proteomics and pS65-Ub kinetics in SH-SY5Y\",\n      \"pmids\": [\"32636217\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Threshold-setting model not tested in vivo\", \"Quantitative kinetics of signal amplification not modeled\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Mapped an active-site residue (W475) governing diubiquitin linkage selectivity, refining the determinants of K6-specificity.\",\n      \"evidence\": \"Genetic code expansion with noncanonical Trp analogues, in vitro diubiquitin DUB assays, and crystallography\",\n      \"pmids\": [\"32484330\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Engineered residues not physiological\", \"Effect on cellular substrate selection untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Extended USP30 substrates to NLRP3, linking it to inflammasome activation outside the mitophagy axis.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, shRNA and inhibitor MF-094 with inflammasome readouts in skin fibroblasts\",\n      \"pmids\": [\"34883112\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab substrate claim\", \"Chain type and direct enzymatic action not fully defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified an autoinhibitory allosteric role for the transmembrane domain, proposing a regulatory mechanism for USP30 catalytic activity.\",\n      \"evidence\": \"Q14 peptide binding by fluorescence polarization and microscale thermophoresis with mitophagy and LIR-motif characterization\",\n      \"pmids\": [\"34989313\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Allosteric mechanism inferred rather than structurally proven\", \"Physiological relevance of TM autoinhibition untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed USP30 stabilizes Snail via K48-chain removal to promote EMT, adding a non-mitochondrial oncogenic substrate.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, knockdown/overexpression with invasion assays in breast cancer cells\",\n      \"pmids\": [\"38146008\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Nuclear/cytosolic site of Snail deubiquitylation unclear given USP30 membrane anchoring\", \"Single-lab claim\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined a benzosulfonamide inhibitor binding mode in the thumb-palm cleft that blocks ubiquitin guidance rather than occluding the active site, informing inhibitor design.\",\n      \"evidence\": \"ABPP MS selectivity, enzyme kinetics, HDX-MS, and computational docking\",\n      \"pmids\": [\"37385347\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular efficacy correlation not central to this study\", \"Docking-inferred rearrangements not crystallographically confirmed here\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified a CDK5-USP30 phosphorylation axis (Ser216) that stabilizes USP30 and suppresses mitophagy while activating MAVS inflammation in Parkinson's disease models.\",\n      \"evidence\": \"Ser216 site mapping, CDK5 inhibition, stability assays, and MPTP/MPP+ models in BV2 cells and mice\",\n      \"pmids\": [\"38772138\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct CDK5 kinase action on USP30 vs indirect effect not fully separated\", \"Single-lab in vivo model\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Expanded the metabolic and cancer substrate set by showing USP30 stabilizes FTO (serine sensing), C/EBPβ (via NPRC), TOMM40, and S100A6 (via HMGA2).\",\n      \"evidence\": \"Co-IP, ubiquitination assays, domain mapping, mass spectrometry, and metabolic/proliferation readouts across cancer and metabolic models\",\n      \"pmids\": [\"41652187\", \"39433172\", \"40227042\", \"39694080\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Several are single-lab substrate claims with limited orthogonal validation\", \"How a membrane DUB accesses these substrates not resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Provided structural and mechanistic detail on specific inhibitor engagement, including a cryptic pocket from switching-loop rearrangement and a covalent inhibitor near catalytic Cys77.\",\n      \"evidence\": \"Crystallography of chimeric USP30-inhibitor complex and HDX-MS/ABPP with covalent inhibitor USP30-I-1\",\n      \"pmids\": [\"40325251\", \"39804742\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo selectivity and pharmacology not addressed structurally\", \"Differential clinical relevance of binding modes unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstrated mitophagy-independent functions: USP30 stabilizes HK1/HK2 to drive glycolysis and stabilizes MAT2A to maintain endothelial barrier function, and its loss improves mitochondrial efficiency independently of PINK1/Parkin.\",\n      \"evidence\": \"Ubiquitinomics with K144R mutagenesis and HK activity assays; EC-specific USP30 KO mice with SAM/methylation readouts; genetic and pharmacological perturbation with bioenergetic assays (one preprint)\",\n      \"pmids\": [\"41688443\", \"41104980\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Breadth of PINK1/Parkin-independent functions not unified\", \"Mechanism of substrate access for soluble metabolic enzymes unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How USP30 substrate selection is partitioned between its TOM-complex quality-control role and the growing list of non-mitochondrial substrates, and how its localization permits access to cytosolic/nuclear targets, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model reconciling membrane anchoring with non-mitochondrial substrates\", \"Physiological hierarchy among substrates unknown\", \"Several candidate substrates rest on single-lab Co-IP evidence\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 3, 4, 8, 22]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 4, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005741\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0005777\", \"supporting_discovery_ids\": [5, 7]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 1, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [1, 5, 7, 9]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [0, 2, 5]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [4, 8, 22]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TOMM20\", \"TOMM40\", \"MFN1\", \"MFN2\", \"DNM1L\", \"PEX2\", \"HK2\", \"GNPAT\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":8,"faith_pct":87.5}}